Caribou Biosciences (CRBU)
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical compa...
- Open
- 1.530
- High
- 1.540
- Low
- 1.455
- Prev. Close
- 1.540
- Volume
- 900.50K
- Turnover
- 1.35M
- Avg Price
- 1.495
- Bid/Ask Ratio
- 37.42%
- Amplitude
- 5.52%
- 52wk High
- 3.535
- Volume Ratio
- 2.63
- Turnover Ratio
- 0.88%
Caribou Biosciences Analyst Rating
View moreForecast & Rating
Aug 14, 2026Price forecast
$11.86712.13%
Forecast & RatingStrong buy
7analysts
- Strong buy85.71%
- Buy14.29%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Aug 18 at 11:13 AM
Equities Analysts Set Expectations for CRBU Q3 Earnings
- Market Beat · Aug 14 at 08:14 PM
Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives Consensus Rating of "Moderate Buy" from Analysts
- Market Beat · Aug 13 at 11:11 PM
Caribou Biosciences (NASDAQ:CRBU) Releases Earnings Results, Beats Expectations By $0.08 EPS
- Earnings Watch · Aug 13 at 08:44 PM
Caribou Biosciences | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 1.499 M
- PUBT · Aug 13 at 11:06 AM
MediWound Q2 FY26 net loss narrows to USD 7.4 million; revenue drops to USD 3.1 million
